Markets

Alnylam Announces Positive Data from Natural History Study - Analyst Blog

Alnylam Pharmaceuticals, Inc.ALNY announced encouraging results from a retrospective natural history study evaluating disease progression in transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) patients suffering from familial amyloidotic cardiomyopathy (FAC).

Results from the study showed that there was an average reduction of 140 meters in the 6-minute walk distance (6-MWD) over an 18-month period in FAC patients suffering from mild-to-moderate heart failure. Alnylam said that it now believes that revusiran has the potential to show a decline from baseline in 6-MWD at 18 months in the ongoing phase III ENDEAVOUR study, which is the co-primary endpoint of the study.

Alnylam is evaluating revusiran in the ENDEAVOUR study in patients suffering from FAC. The company is currently enrolling patients in this randomized, double-blind, placebo-controlled, global study. Patients completing the ENDEAVOUR study will be eligible for a phase III open label extension study.

We remind investors that Alnylam is in collaboration with Sanofi SNY for the development and commercialization of RNAi therapeutics across the world.

Alnylam currently has no approved product in its portfolio. Although the company has a number of pipeline candidates, most of the candidates are in early or mid stages of development. The successful development and commercialization of revusiran is crucial for the company.

Alnylam currently carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the health care sector include Acorda Therapeutics, Inc. ACOR and Cytokinetics, Inc. CYTK . Both carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ALNYLAM PHARMA (ALNY): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

ACORDA THERAPT (ACOR): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALNY CYTK ACOR SNY

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More